





# 20 – 21 November 2019 Pravasi Bharatiya Kendra, New Delhi, India

# Draft Programme Outline

# Day 1: 20 November 2019

1100 – 1200	Inaugural Session
1200 – 1300	Dignitaries inaugurate and take a round of the Exposition Tea/Coffee-B2B Networking Break
1300 – 1430	Partner State/Country Session over lunch
1430 – 1700	Parallel Sectoral Sessions

### Parallel Session 1: Smart Cities: Current Scenario And Way Forward

The Government of India launched the Smart Cities Mission over 4 years ago with the objective to promote sustainable and inclusive cities that provide core infrastructure and give a good quality of life to the citizens, a clean and sustainable environment and application of 'Smart' Solutions. The mission of the scheme is to provide examples which can be replicated both within and outside the Smart city. The theme of the session is to deliberate and share knowledge on various components of Smart Cities with regards to the Smart City framework and implementation; and discuss the best solutions with a way forward.

### Parallel Session 2: The Rise of Renewables In India: Emerging Challenges & Opportunities

India has set an ambitious renewable energy capacity expansion target of 175GW by 2022, and over 500GW by 2030. This session will detail India's recent strides in renewables and present the major opportunities for investment, technology development and deployment, storage, demand enhancement and market creation. Discussions will cover challenges arising from the rapidly rising share of renewables in India's energy mix, such as establishing a conducive policy framework for research and innovation; attracting low-cost and innovative financing mechanisms; extensive grid integration of renewables, and outreach to a wide range of consumers, and strategize upon a proactive roadmap.

### Parallel Session 3: Destination India: Contract Manufacturing And Research Services

The rising costs and regulatory pressures in developed markets are forcing many global pharmaceutical companies to reduce their internal capacities in research and development (R&D), and manufacturing, and turn to contract manufacturing and research services (CRAMS) and outsourcing of research and clinical trials to developing countries. These strategies help multinational companies reduce costs, increase development capacity, and focus on their core profit makings activities, such as drug discoveries and marketing, rather than on manufacturing. India, with a large patient population and genetic pool, is fast emerging as a preferred destination for such multinationals seeking efficiencies of cost and time.

#### Parallel Session 4: The 3Cs Of AI (Connection-Collaboration-Co-Creation)

Al in an individual's life is already making a positive difference and will fuel the next wave of economic growth. NITI Aayog, India's think tank, took a significant step and published the first-of-its-kind discussion paper entitled "National Strategy for Artificial Intelligence #AIFORALL", which gives a compass for governments, academia, and entrepreneurs as we embark on this emerging technological frontier. But to utilize the strength of AI and address its challenges, a global collaboration between the private and public sectors is critical and that can play an important role. Various global strategic platforms such as IE29BF, therefore, need to come together to engage in the development of universal, voluntary, and consensus-based standards and best practices both for private and public users of AI. Hence, this journey will not be without its challenges and requires a comprehensive Connection-Collaboration-Co-creation to reinforce AI-related research, foster and attract top-level talent, and create breakthroughs to lay a solid foundation.

# Day 2: 21 November 2019

0930 – 1030	B2B Networking
1030 – 1215	Parallel Sectoral Sessions

#### Parallel Session 1: Digital Technology and Smart Cities

Technology is continuously evolving in the smart city environment with the digital information and data playing a key role. Traditional command-and-control methods of urban management enter a new paradigm that interconnects the entire Smart city. This session will discuss interoperability of systems, data, communication & services between cities and global suppliers as well as the aspects of data security.

#### Parallel Session 2: Innovative Financing Solutions for Renewable Energy

During the last few years the global investment in renewable energy space remained at around US\$300 billion. Though with decreasing cost of renewable energy technologies, renewable energy capacity addition globally has gone up. To maintain the 1.5degree scenario, the investment in renewables need to grow exponentially. To meet the above challenge, it is necessary to create financing eco-system for renewable energy. Therefore, this session will discuss the financing communities' perspective regarding allocation and re-cycling of capital investments, innovative financial models, plausible innovative finance framework to reach this goal. The perspective may vary across the globe depending upon government's policy, regulatory framework, the stage of growth, maturity level and success of RE in various regions

#### Parallel Session 3: India - A High-Quality Global Pharma Manufacturing Hub

India is among the leading global producers of cost-effective generic medicines and vaccines, supplying 20% of the total global demand by volume. The country has an established domestic pharmaceutical industry, a strong network of 3000 drug companies and about 10,500 manufacturing units. Out of these, 1,400 units are World Health Organization (WHO) good manufacturing practices (GMP) approved; 1,105 have Europe's certificate of suitability (CEPs); more than 950 fulfil the therapeutic goods administration (TGA) guidelines; and 584 sites are approved by the US Food and Drug Administration (USFDA). India also has the expertise for active pharmaceutical ingredients (APIs) and sees significant opportunities for value-creation. Various policy initiatives and schemes from GOI offer investment opportunities in the production of API or bulk drugs, biosimilars, vaccines, neutraceuticals, as well as food and drug testing and contract research.

#### Parallel Session 4: Digital Technology

Digital is vital for business transformation, workplace efficiency and service productivity. To transform and remain competitive in the era of industry 4.0, enterprises embrace digital to create improved and personalized customer offerings and gain new revenue streams. This session will discuss the significance of technology not just for business benefits, but to create sustainable and inclusive industries of the future through digital transformation. Deliberations would include the role of leadership in driving digital adoption and importance of right strategy to win the global marketplace.

1230 – 1315	Valedictory Session
1315 – 1415	Partner State/Country Session over Lunch
1415 – 1500	Forum ends